All sponsors

Ferring Pharmaceuticals

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-19
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%

Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +23.0 months). See all sponsors →

Open Ferring Pharmaceuticals on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
PICCOLO
NCT04113382
P1/2RecruitingBowel Preparation392027-12 (+81 mo)
ABLE-22
NCT06545955
P3RecruitingNon-muscle Invasive Bladder Cancer With Carcinoma in Situ2502028-06-30 (+23 mo)
ABLE-32
NCT06510374
P3RecruitingIntermediate Risk Non-Muscle Invasive Bladder Cancer4542028-09-30 (+2 mo)
LUNAR
NCT06668493
P1/2RecruitingLow-grade Upper Tract Urothelial Carcinoma202029-11-30
FE 999326
NCT05704244
P3Active, not recruitingBladder Cancer252029-11-30 (+59 mo)